156 related articles for article (PubMed ID: 31714968)
1. "Electronic Nose" Predicts Immunotherapy Response.
Abbasi J
JAMA; 2019 Nov; 322(18):1756. PubMed ID: 31714968
[No Abstract] [Full Text] [Related]
2. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
3. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
Rusch VW; Chaft J; Hellmann M
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
[No Abstract] [Full Text] [Related]
4. [The predicive biomarkers of programmed death receptor-l/ligand antibodes in the treatement of non-small-cell lung cancer].
Xu Y; Bai L
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):799-803. PubMed ID: 30347553
[No Abstract] [Full Text] [Related]
5. Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.
Mansfield AS; Dong H
Clin Pharmacol Ther; 2016 Sep; 100(3):220-2. PubMed ID: 26916808
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in non-small cell lung cancer: The past, the present, and the future.
Lu M; Su Y
Thorac Cancer; 2019 Apr; 10(4):585-586. PubMed ID: 30821103
[No Abstract] [Full Text] [Related]
7. Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities.
Ilie M; Benzaquen J; Hofman V; Lassalle S; Yazbeck N; Leroy S; Heeke S; Bence C; Mograbi B; Glaichenhaus N; Marquette CH; Hofman P
Curr Mol Med; 2017; 17(8):527-540. PubMed ID: 29473504
[TBL] [Abstract][Full Text] [Related]
8. Baseline corticosteroids reduce activity of PD-L1 blockade.
Gourd E
Lancet Oncol; 2018 Oct; 19(10):e515. PubMed ID: 30177497
[No Abstract] [Full Text] [Related]
9. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.
Nadal E; Massuti B; Dómine M; García-Campelo R; Cobo M; Felip E
Cancer Immunol Immunother; 2019 Mar; 68(3):341-352. PubMed ID: 30725206
[TBL] [Abstract][Full Text] [Related]
10. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
Wu Y; Lin L; Shen Y; Wu H
Int J Cancer; 2018 Dec; 143(11):3038-3040. PubMed ID: 29987914
[No Abstract] [Full Text] [Related]
11. Hypoxia-inducible factor-2α and refractory nsclc: Further evidence to support the use of immune-checkpoint inhibitors?
Mormile R
Pulm Pharmacol Ther; 2019 Aug; 57():101815. PubMed ID: 31278977
[No Abstract] [Full Text] [Related]
12. Lung cancer: Squiring immunotherapy to CheckMate.
Hutchinson L
Nat Rev Clin Oncol; 2015 Aug; 12(8):436. PubMed ID: 26122186
[No Abstract] [Full Text] [Related]
13. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
Sgambato A; Casaluce F; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Drug Saf; 2016; 11(1):62-8. PubMed ID: 26412670
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy: pembrolizumab-is the writing on the wall for cancer?
Hutchinson L
Nat Rev Clin Oncol; 2015 Jul; 12(7):371. PubMed ID: 25963092
[No Abstract] [Full Text] [Related]
15. Pseudoprogression and Immune-Related Response in Solid Tumors.
Chiou VL; Burotto M
J Clin Oncol; 2015 Nov; 33(31):3541-3. PubMed ID: 26261262
[No Abstract] [Full Text] [Related]
16. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
Park SE; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
J Thorac Oncol; 2018 Jan; 13(1):106-111. PubMed ID: 29101058
[TBL] [Abstract][Full Text] [Related]
17. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Villaruz LC; Socinski MA
Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in advanced non-small cell lung cancer.
Assi HI; Kamphorst AO; Moukalled NM; Ramalingam SS
Cancer; 2018 Jan; 124(2):248-261. PubMed ID: 29211297
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
